Press release
Savara Obtains Global Rights to Develop and Commercialize Apulmiq
Management to Host Conference Call / Webcast with Bronchiectasis Expert Dr. James Chalmers AUSTIN, Texas--(BUSINESS WIRE)-- Savara Inc. (Nasdaq: SVRA), an
About this update from Savara, Inc.
[{"type":"text","content":"\nManagement to Host Conference Call / Webcast with Bronchiectasis Expert Dr. James Chalmers \n\n AUSTIN, Texas--(BUSINESS WIRE)--\nSavara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced the Company has entered into an exclusive license and collaboration agreement with Grifols for Apulmiq (inhaled liposomal ciprofloxacin). Also known as Linhaliq in Europe, Apulmiq is a late-stage investigational inhaled antibiotic in Phase 3 development for the treatment of non-cystic fibrosis bronchiectasis (NCFB).\n\n\n“We are very excited about Apulmiq and believe it represents a transformational addition to our pipeline,” said Rob Neville, Savara’s Chief Executive Officer. “Acquiring the rights provides us with another high potential Phase 3 program that leverages our core capabilities in inhaled orphan drug development and complements our existing pipeline. With an estimated prevalence of more than 150,000 NCFB patients in the U.S. and potentially more in Europe, Apulmiq could represent a game-changing opportunity in a therapeutic area with little competition and significant unmet need. Our goal is to offer a novel pharmaceutical treatment option to patients living with this chronic and debilitating disease.”\n\n\nUnder the terms of the agreement, Savara has obtained the worldwide rights to develop and commercialize Apulmiq. Savara provided an upfront payment and, if regulatory approval is obtained, Grifols will be eligible for regulatory milestone payments as well as royalties and potential tiered sales milestones upon commercialization.\n\n\n“I am excited that Savara will be advancing this important investigational therapy,” said James Chalmers, MBChB, PhD, Chair of EMBARC, the European Bronchiectasis Registry and British Lung Foundation Professor of Respiratory Research at the University of Dundee. “I look forward to working with Savara on the confirmatory Phase 3 study that will benefit from the learnings of previous clinical studies of Apulmiq and other inhaled antibiotics in NCFB. Bronchiectasis patients have no approved drug options available and I believe many patients could substantially benefit from an effective inhaled antibiotic.”\n\n\nThe Company expects to work with regulatory agencies to plan a confirmatory Phase 3 study. Key learnings from previous studies of inhaled antibiotics for NCFB will be leverage...